BRAF and melanoma: In this study, we investigated the effect of HDACi treatment alone and in combination with the BRAF inhibitor, vemurafenib, on PMCA expression and on Ca2+ clearance in both BRAF-mutant and BRAF wild-type melanoma cell lines.